See more : Battery Minerals Limited (BAT.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Generation Bio Co. (GBIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Generation Bio Co., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Echo Therapeutics, Inc. (ECTE) Income Statement Analysis – Financial Results
- Polyphor AG (POLN.SW) Income Statement Analysis – Financial Results
- Indian Oil Corporation Limited (IOC.NS) Income Statement Analysis – Financial Results
- Zodiac Ventures Limited (ZODIACVEN.BO) Income Statement Analysis – Financial Results
- Primavera Capital Acquisition Corporation (PV) Income Statement Analysis – Financial Results
Generation Bio Co. (GBIO)
About Generation Bio Co.
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 5.90M | 0.00 | 0.00 | 0.00 | 0.00 | 36.00K |
| Cost of Revenue | 79.82M | 5.13M | 4.53M | 3.43M | 1.86M | 0.00 |
| Gross Profit | -73.91M | -5.13M | -4.53M | -3.43M | -1.86M | 36.00K |
| Gross Profit Ratio | -1,251.88% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 93.62M | 96.72M | 85.25M | 58.53M | 50.13M | 28.15M |
| General & Administrative | 50.85M | 44.46M | 33.85M | 22.58M | 12.17M | 9.18M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 50.85M | 44.46M | 33.85M | 22.58M | 12.17M | 9.18M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 144.47M | 141.18M | 119.10M | 81.11M | 62.30M | 37.33M |
| Cost & Expenses | 144.47M | 141.18M | 119.10M | 81.11M | 62.30M | 37.33M |
| Interest Income | 11.95M | 4.54M | 187.00K | 591.00K | 975.00K | 0.00 |
| Interest Expense | 0.00 | 4.54M | 50.00K | 591.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 5.26M | 5.13M | 4.53M | 3.43M | 1.86M | 347.00K |
| EBITDA | -133.30M | -136.05M | -114.57M | -77.68M | -60.44M | -36.95M |
| EBITDA Ratio | -2,257.79% | 0.00% | 0.00% | 0.00% | 0.00% | -102,630.56% |
| Operating Income | -138.56M | -141.18M | -119.10M | -81.11M | -62.30M | -37.29M |
| Operating Income Ratio | -2,346.93% | 0.00% | 0.00% | 0.00% | 0.00% | -103,594.44% |
| Total Other Income/Expenses | 11.95M | 4.54M | -50.00K | 591.00K | 985.00K | 1.49M |
| Income Before Tax | -126.61M | -136.64M | -119.15M | -80.52M | -61.32M | -35.80M |
| Income Before Tax Ratio | -2,144.51% | 0.00% | 0.00% | 0.00% | 0.00% | -99,452.78% |
| Income Tax Expense | 0.00 | -4.54M | -4.48M | -4.02M | -985.00K | 1.49M |
| Net Income | -126.61M | -132.10M | -114.67M | -76.50M | -60.33M | -35.80M |
| Net Income Ratio | -2,144.51% | 0.00% | 0.00% | 0.00% | 0.00% | -99,452.78% |
| EPS | -1.96 | -2.27 | -2.04 | -2.81 | -1.31 | -1.82 |
| EPS Diluted | -1.96 | -2.27 | -2.04 | -2.81 | -1.31 | -1.82 |
| Weighted Avg Shares Out | 64.48M | 58.11M | 56.30M | 27.26M | 46.21M | 19.69M |
| Weighted Avg Shares Out (Dil) | 64.48M | 58.11M | 56.30M | 27.26M | 46.21M | 19.69M |
Generation Bio to Present at the 2022 Jefferies Healthcare Conference
CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in...
Generation Bio to Present at 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that the company will present at the virtual 40th Annual J.P....
SHAREHOLDER ALERT: Robbins LLP Investigates Generation Bio Co. (GBIO) on Behalf of Shareholders
SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Generation Bio Co. (NASDAQ: GBIO) to determine whether certain Generation Bio officers and directors violated the Securities Exchange Act of 1934 and breached fiduciary duties to shareholders. Generation Bio develops...
Generation Bio Hits 52-Week Low After Preclinical Data From Hemophilia A Program
Generation Bio Co (NASDAQ: GBIO) provided an update on factor VIII expression from a series of mouse and companion non-human primate (NHP) studies in hemophilia A and an update on its development non-viral genetic medicine platform. In mouse studies, rapid enzymatic synthesis (RES)-derived...
Generation Bio to Present at Jefferies Virtual Gene Therapy/Editing Summit
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate...
Generation Bio to Present at European Society of Gene and Cell Therapy 2021 Annual Virtual Congress
CAMBRIDGE, Mass., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced an oral presentation at the European Society of Gene and Cell...
Generation Bio Reports Business Highlights and Second Quarter 2021 Financial Results
CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported recent business highlights and second quarter 2021 financial results.
Generation Bio to Present at Wedbush PacGrow Healthcare Conference 2021
CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate...
Generation Bio Announces Plan to Scale Next-Generation Rapid Enzymatic Manufacturing Process Across Portfolio and Provides Pipeline Update
Company to transition all portfolio programs to rapid enzymatic synthesis (RES), enabling improved quality, scale and speed of closed-ended DNA manufacturing
Generation Bio to Present at William Blair Biotech Focus Conference
CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at...
Source: https://incomestatements.info
Category: Stock Reports